Experienced in T-Cell Lymphoma

Dr. Jie J. Wang

Family Medicine
Kaiser Foundation Health Plan Of The Northwest
10180 Se Sunnyroad Rd, 
Clackamas, OR 
Experienced in T-Cell Lymphoma
Kaiser Foundation Health Plan Of The Northwest
10180 Se Sunnyroad Rd, 
Clackamas, OR 
OverviewInsuranceLocationsClinical Research

Overview

Jie Wang is a primary care provider, practicing in Family Medicine in Clackamas, Oregon. Dr. Wang is rated as an Experienced provider by MediFind in the treatment of T-Cell Lymphoma. Her top areas of expertise are Diabetic Retinopathy, Retinopathy Pigmentary Mental Retardation, Cardiomyopathy, and Diabetic Macular Edema (DME).

Her clinical research consists of co-authoring 399 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles and participated in 1 clinical trial in the study of T-Cell Lymphoma.

Specialties
Family Medicine
Licenses
Family Medicine in WI
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD

Locations

KAISER FOUNDATION HEALTH PLAN OF THE NORTHWEST
10180 Se Sunnyroad Rd, Clackamas, OR 97015
Other Locations
KAISER FOUNDATION HEALTH PLAN OF THE NORTHWEST
2400 Lancaster Dr Ne, Salem, OR 97305
KAISER FOUNDATION HEALTH PLAN OF THE NORTHWEST
10100 Se Sunnyside Rd, Clackamas, OR 97015
KAISER FOUNDATION HEALTH PLAN OF THE NORTHWEST
4855 Sw Western Ave, Beaverton, OR 97005

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Enrollment Status: Completed
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: Duvelisib
Study Phase: Phase 2
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological
Study Drugs: MGD013, MGD013+Margetuximab
Study Phase: Phase 1
A Phase I/Ib Pilot Study to Determine the Safety and Efficacy of a Human Anti-glucagon Receptor Antibody (REMD-477) in Controlling Severe Hyperglycemia Due to Copanlisib in Patients With Relapsed or Refractory Lymphoma
A Phase I/Ib Pilot Study to Determine the Safety and Efficacy of a Human Anti-glucagon Receptor Antibody (REMD-477) in Controlling Severe Hyperglycemia Due to Copanlisib in Patients With Relapsed or Refractory Lymphoma
Enrollment Status: Terminated
Publish Date: June 11, 2021
Intervention Type: Biological
Study Phase: Phase 1
View 2 Less Clinical Trials

2 Total Publications

EIF4A3 Enhances the Proliferation and Cell Cycle Progression of Keloid Fibroblasts by Inducing the hsa_circ_0002198 Expression.
EIF4A3 Enhances the Proliferation and Cell Cycle Progression of Keloid Fibroblasts by Inducing the hsa_circ_0002198 Expression.
Journal: Clinical, cosmetic and investigational dermatology
Published: September 02, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wang's expertise for a condition
ConditionClose
    View All 67 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile